Standard BioTools Inc.
LAB
$1.50
$0.074.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.61% | -65.23% | 3.25% | -24.80% | -4.15% |
| Total Depreciation and Amortization | 58.52% | -37.55% | -60.66% | -42.69% | -28.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,030.08% | 980.14% | 3,027.31% | -71.17% | -90.34% |
| Change in Net Operating Assets | 83.13% | 29.36% | 26.43% | -1,176.47% | -796.74% |
| Cash from Operations | 39.21% | 26.87% | -14.37% | -231.40% | -196.35% |
| Capital Expenditure | -259.96% | -613.04% | -310.88% | -126.70% | 11.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.49% | -100.49% | -100.49% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,693.85% | 319.20% | 21.53% | 76.38% | -103.69% |
| Cash from Investing | -81.14% | -87.89% | -79.77% | 1,694.60% | 340.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -482.50% | -435.28% | -435.28% | -2,933.70% | -1,033.49% |
| Issuance of Common Stock | 48.48% | 57.24% | -34.04% | -19.59% | -23.05% |
| Repurchase of Common Stock | 96.44% | 96.90% | 98.86% | -101.39% | -89.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | 100.00% | -- | -- |
| Cash from Financing | -11.14% | -8.35% | -245.77% | -1,407.06% | -708.08% |
| Foreign Exchange rate Adjustments | 439.20% | 658.06% | -3,080.00% | -2,147.06% | -267.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.79% | -185.86% | -177.56% | 490.01% | 583.59% |